MBX Biosciences, a biopharmaceutical company, announced updates on its clinical programs at the 44th Annual J.P. Morgan Healthcare Conference. One-year follow-up data for once-weekly canvuparatide in hypoparathyroidism expected in Q2 2026, with Phase 3 initiation in Q3 2026. Additionally, 12-week data for MBX 4291, a dual GLP-1/GIP co-agonist prodrug for obesity, anticipated in Q4 2026. Two new obesity candidates nominated for once-monthly dosing in 2026. The company has a strong cash position of approximately $373.7 million as of December 31, 2025, expected to fund operations into 2029.

In the Phase 2 trial, once-weekly canvuparatide showed high responder rates and well-tolerated dosing for hypoparathyroidism. Full 12-week and one-year follow-up data to be shared in Q2 2026. MBX plans to begin Phase 3 trial in Q3 2026.

MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity, is progressing with 12-week data expected in Q4 2026. Two new obesity candidates, including an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, are set for nomination in 2026.

Long-acting Imapextide (MBX 1416) data for post-bariatric hypoglycemia expected in Q2 2026. Preliminary cash position of approximately $373.7 million as of December 31, 2025, to sustain operations into 2029.

Read more at GlobeNewswire: MBX Biosciences to Provide 2026 Outlook and Business Update